Evidence map›Paper›PMID 36351580›Full record

ReviewInternal medicine (Tokyo, Japan)2023

New-onset Adult-onset Still's Disease Following COVID-19 Vaccination: Three Case Reports and a Literature Review.

Mayumi Matsuda, Yu Funakubo Asanuma, Kazuhiro Yokota, Sakon Sakai, Hiroaki Yazawa, Takashi Maruyama, Takuma Tsuzuki Wada, Yasuto Araki, Toshihide Mimura

Open access · diamondAbstract readReviewCase Reports
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mayumi MatsudaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Yu Funakubo AsanumaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Kazuhiro YokotaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Sakon SakaiDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Hiroaki YazawaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Takashi MaruyamaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Takuma Tsuzuki WadaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Yasuto ArakiDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Toshihide MimuraDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Saitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since December 2020, coronavirus disease 2019 (COVID-19) vaccines have been distributed in most countries to prevent the onset and aggravation of COVID-19. There is little information regarding the long-term safety of the vaccines. We report three cases and a literature review of new-onset adult-onset Still's disease (AOSD) that occurred following COVID-19 vaccination. Our cases include moderate to severe AOSD, and two were complicated with macrophage activation syndrome. Seventeen cases of new-onset or relapse of AOSD following COVID-19 vaccination, including 14 identified in the literature review and our 3 patients, were all treated successfully with glucocorticoid therapy, immunosuppressive drugs, or biologic agents.

Indexed as

COVID-19COVID-19 VaccinesStill's Disease, Adult-OnsetAdultHumansImmunosuppressive AgentsVaccinationCOVID-19 VaccinesImmunosuppressive Agentsadult-onset Still's diseaseCOVID-19 vaccineinnate immune response

Identifiers

PMID36351580
PMCPMC9908393
OpenAlexW4308577263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.